Ossianix Announces Lundbeck Investment by EON


More Info
									Ossianix Announces Lundbeck Investment
January 03, 2012 12:04 AM Eastern Time 

PHILADELPHIA--(EON: Enhanced Online News)--Ossianix, Inc. today announced a strategic investment by H.
Lundbeck A/S in the form of a Convertible Promissory Note. The proceeds from Lundbeck’s investment is
expected to allow Ossianix to generate biopharmaceuticals for the treatment of nervous system disorders by utilizing
Ossianix’s proprietary single domain antibody platform modeled on the shark vNAR structure. This will potentially
give access to the development of novel differentiated CNS products. Lundbeck will retain the right to negotiate for
certain products and technologies arising from the research at Ossianix.

“Lundbeck is a recognized leader in producing drugs for neurological and psychiatric disorders. We are very pleased
that Lundbeck via this investment has chosen to further extend their involvement in the emerging field of
biotherapeutics for CNS disorders,” said Frank S. Walsh, CEO of Ossianix. “We also welcome Peter Høngaard 
Andersen, Senior Vice President, External Scientific Relations to the Board of Directors of Ossianix and we will
benefit immensely from his wide experience within both Pharma and Biotech.” 

Peter Høngaard Andersen said, “We at Lundbeck look forward to following the development of Ossianix’s exciting
new technology. We wish to develop our biologics portfolio further and Ossianix’s technology has the potential to
tailor the power of the single domain antibodies to a variety of unique drug targets.” 

About Ossianix

Ossianix is a privately held biopharmaceutical company based in Philadelphia, PA that develops novel
biopharmaceuticals for a variety of therapeutic areas. The company utilizes the versatile single domain shark vNAR
scaffold to engineer unique differentiated products in a variety of formats. Two former senior executives from Wyeth
and Pfizer, Frank S. Walsh and Corey S. Goodman, formed the company in 2011. Ossianix is currently funded by
BioAdvance and the ALS Association. For more information please visit www.ossianix.com.

About Lundbeck

H. Lundbeck A/S (LUN.CO, LUNDC, HLUKY) is an international pharmaceutical company highly committed to
improving quality of like for people suffering from CNS disorders. For this purpose Lundbeck is engaged in the
research, development, production, marketing and sales of pharmaceuticals across the world. The company’s
products are targeted at disorders such as depression and anxiety, schizophrenia, insomnia, epilepsy and
Huntingdon’s, Alzheimer’s and Parkinson’s diseases.

Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen Denmark. Today Lundbeck employs
approximately 5,900 people worldwide. Lundbeck is one of the worlds leading companies working with CNS
disorders. In 2010 the company’s revenue was DKK 14.8 billion (approximately EUR 2.0 billion or USD 2.6
billion). For more information please visit www.lundbeck.com.

About BioAdvance

Through its Greenhouse Fund, BioAdvance, has committed $20 million in 49 life science start-up companies and
academic technologies. BioAdvance investments have enabled its portfolio companies to leverage $1.4 billion in
follow-on capital and M&A valuations. To date, seven BioAdvance portfolio companies have been acquired and an
eighth has gone public (Nupathe:PATH). The BioAdvance portfolio companies are developing 60 products to treat
diseases such as cancer, diabetes, Alzheimer’s and infectious diseases.
For more information or to apply for funding please visit www.bioadvance.com.

Ossianix Inc
Dr. Frank S. Walsh, CEO, 484-767-2843
Jennifer Smith, 610-230-0645

Release Tags
   l   H. Lundbeck A/S
   l   Ossianix

News by Industry

   l   Biotechnology (Health & Medicine)
   l   Business
   l   Health & Medicine
   l   Pharmaceuticals
   l   Science

News by Subject

   l   Funding

News by Geography

   l   Denmark
   l   Europe
   l   North America
   l   Pennsylvania
   l   United States

Release Summary
Ossianix Inc announces a strategic investment by H. Lundbeck A/S of Denmark.

Ossianix Inc
           Opens in new window
   l                             Website

   l       News Feed


To top